1-16 of 16
Keywords: Mitoxantrone
Close
Sort by
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1995) 52 (1): 60–65.
Published Online: 30 June 2009
... to either methotrexate (10 -6 -10 -4 M ), doxorubicin (10 -7 -10 -5 M ) or mitoxantrone (10 -7 -10 -5 M). In HPMC exposed to doxorubicin (10 -6 M ) the intracellular transport of potassium, as assessed with 86 Rb as its analogue, was not affected. Methotrexate (10 -5 M ) diminished Na, K-ATPase activity...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1995) 52 (6): 435–438.
Published Online: 30 June 2009
...M. Colleoni; P. Nelli; F. Gaion; G. Sgarbossa; P. Manente The combination chemotherapy including mitoxantrone, fluorouracil and leucovorin has proven to be effective and well-tolerated in advanced breast cancer (ABC). No data are available on the association with navelbine, a new vinka alkaloid...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1996) 53 (6): 482–487.
Published Online: 30 June 2009
...J.S. Nel; Carta I. Falkson Forty-one patients with acute non-lymphoblastic leukemia were treated between March 1990 and November 1993 with mitoxantrone, cytarabine, etoposide and granulocyte-macrophage-colony-stimulating factor (GM-CSF) started on day 1. This was given as induction, consolidation...
Journal Articles
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1989) 46 (4): 208–211.
Published Online: 26 June 2009
...W.R. Bezwoda; R. Dansey; L. Seymour Seventy-five patients with stage 4 breast cancer were treated with a first-line chemotherapy regimen consisting of cyclophosphamide 600 mg/m 2 , mitoxantrone 12 mg/m 2 , and vincristine 1.4 mg/m 2 (CNV). Objective response was seen in 61/75 (81%) with 17/75 (23...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (2): 112–114.
Published Online: 26 June 2009
...Magnus Björkholm; Johanna Björnsdottir; Leif Stenke; Gunnar Grimfors In a phase I/II study mitoxantrone and etoposide, in combination with cytarabine, were given to 26 patients with refractory, relapsed, and previously untreated acute nonlymphocytic leukemia. Therapy consisted of mitoxantrone 12 mg...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (2): 166–169.
Published Online: 26 June 2009
...Narayana S. Kamath; Manik P. Chitnis The efficacy of dipyrone to modulate antitumor activity of mitoxantrone (MTN) and doxorubicin (DOX) was studied in vivo in mice bearing P388 murine lymphocytic leukemia sensitive (P388/S) and resistant (P388/DOX) to DOX. P388/DOX-bearing mice demonstrated...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1990) 47 (6): 508–515.
Published Online: 26 June 2009
...I. Fichtner; M. Becker; M. Lemm; G. Winterfeld A normally, relatively sensitive P 388 developed resistance within few passages (P 388/Mitox) by in vivo treatment with suboptimal doses (1 mg/kg i.v.) of mitoxantrone. This resistance remained stable over 50 generations without further drug treatment...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1989) 46 (2): 128–131.
Published Online: 26 June 2009
...K. Satyamoorthy; M.P. Chitnis; S.G. Pradhan; S.H. Advani Calcium channel-blocking agent verapamil has been established to be an effective drug to modulate the action of many anticancer drugs. In this study, we examined the effect of verapamil on the cytotoxicity of mitoxantrone in human chronic...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1992) 49 (2): 139–142.
Published Online: 26 June 2009
.... In this study the feasibility and efficacy were evaluated of a treatment with mitoxantrone (dihydroxyanthracenedione, DH AD), 12 mg/m 2 i.v.onday 1 every 3 weeks. We included 18 patients with poor-risk HCC ineligible for our other trials in relation to their performance status [8], pretreatments [6], age over...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1988) 45 (4): 273–275.
Published Online: 25 June 2009
...Alec Goldenberg; David Kelsen; Pasquale Benedetto A Phase II trial of mitoxantrone was performed in patients with advanced adenocarcinoma of the stomach. All patients had measurable or evaluable disease, and none had received prior chemotherapy. Mitoxantrone was administered intravenously at a dose...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1988) 45 (5): 378–379.
Published Online: 25 June 2009
...Daniel A. Vorobiof; Aletta P. S. Terblanche; Carla I. Falkson; Geoffrey Falkson Twenty-two patients with histologically confirmed non-Hodgkin’s lymphoma received treatment with a chemotherapy combination containing cyclophosphamide, mitoxantrone, vincristine and prednisone. Leukopenia, nausea...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1987) 44 (1): 47–50.
Published Online: 23 June 2009
...Manik P. Chitnis; Narayana S. Kamath The effect of dipyrone along with doxorubicin and mitoxantrone was studied alone and in combination on the 3 H-thymidine ( 3 H-TdR) incorporation in P388 leukaemia sensitive (P388/S) and resistant (P388/ADR) to doxorubicin. Dipyrone 10 –– 4 M demonstrated...
Journal Articles
Subject Area:
Oncology
Journal: Oncology
Oncology (1986) 43 (4): 264–267.
Published Online: 23 June 2009
... in order to determine their capacity to damage cardiac cells. Mitoxantrone is an anthracenedione derivative with structural and functional similarities to doxorubicin. Comparative trials on rat suggest that mitoxantrone induced cardiac toxicity might be less marked than that caused by doxorubicin, while...
Journal Articles